000K utf8 1100 2024$c2024-06-14 1500 eng 2050 urn:nbn:de:hbz:465-20250227-163734-4 2051 10.1038/s41598-024-64302-2 3000 Richlitzki, Cedric 3010 Aigner, Clemens 3010 Bölükbas, Servet 3010 Darwiche, Kaid 3010 Eberhardt, Wilfried E. E. 3010 Guberina, Maja 3010 Guberina, Nika 3010 Hautzel, Hubertus 3010 Metzenmacher, Martin 3010 Pöttgen, Christoph 3010 Schuler, Martin 3010 Stuschke, Martin 3010 Theegarten, Dirk 3010 Wiesweg, Marcel 4000 C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy [Richlitzki, Cedric] 4209 To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation. Cross validated classifiers including biomarkers in addition to important clinical parameters were compared with classifiers containing the clinical parameters alone. An increased C-reactive protein (CRP) value in the final week of radiotherapy was found as a prognostic factor for overall survival, both as a continuous (HR 1.099 (1.038–1.164), p < 0.0012) as well as categorical variable splitting data at the median value of 1.2 mg/dl (HR 2.214 (1.388–3.531), p < 0.0008). In the multivariable analysis, the CRP value-maintained significance with an HR of 1.105 (1.040–1.173) and p-value of 0.0012. The cross validated classifier using CRP at the end of radiotherapy in addition to clinical parameters separated equally sized high and low risk groups more distinctly than a classifier containing the clinical parameters alone (HR = 2.786 (95% CI 1.686–4.605) vs. HR = 2.287 (95% CI 1.407–3.718)). Thus, the CRP value at the end of radiation therapy has successfully passed the crucial cross-validation test. The presented data on CRP levels suggests that inflammatory markers may become increasingly important during definitive radiochemotherapy, particularly with the growing utilization of immunotherapy as a consolidation therapy for stage III NSCLC. 4950 https://doi.org/10.1038/s41598-024-64302-2$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:hbz:465-20250227-163734-4$xR$3Volltext$534 4961 https://duepublico2.uni-due.de/receive/duepublico_mods_00082405 5051 610 5550 C-reactive protein (CRP) 5550 Definitive radiochemotherapy 5550 ESPATUE trial 5550 Laboratory values 5550 Overall survival 5550 Stage III non-small cell lung cancer (NSCLC)